Literature DB >> 31026090

LncRNA PTCSC3 inhibits triple-negative breast cancer cell proliferation by downregulating lncRNA H19.

Ning Wang1, Mingsheng Hou1, Ying Zhan1, Xiaobin Sheng1.   

Abstract

Long noncoding RNA (lncRNA) PTCSC3 (hereafter PTCSC3 is used to represent lncRNA PTCSC3) inhibits glioma and thyroid cancer, indicating its potential tumor suppression function in other types of cancers. We explored the potential involvement of PTCSC3 in triple-negative breast cancer (TNBC). In the current study, we found that PTCSC3 was downregulated in tumor tissues of patients with TNBC. PTCSC3 expression was positively correlated with plasma levels of PTCSC3. LncRNA H19 was upregulated and was inversely correlated with PTCSC3 in tumor tissues. PTCSC3 overexpression led to downregulated H19 in TNBC cells, while H19 overexpression did not affect PTCSC3 expression. PTCSC3 inhibited and H19 promoted proliferation of TNBC cells. H19 overexpression attenuated the effects of PTCSC3 overexpression. Cancer cell migration and invasion were not significantly affected by PTCSC3 overexpression. Therefore, lncRNA PTCSC3 inhibits TNBC cell proliferation by downregulating lncRNA H19.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  long noncoding RNA H19; long noncoding RNA PTCSC3; proliferation; triple-negative breast cancer

Year:  2019        PMID: 31026090     DOI: 10.1002/jcb.28769

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

Review 1.  Roles of miRNA and lncRNA in triple-negative breast cancer.

Authors:  Juan Xu; Kang-Jing Wu; Qiao-Jun Jia; Xian-Feng Ding
Journal:  J Zhejiang Univ Sci B       Date:  2020 Sept.       Impact factor: 3.066

2.  LncRNA PTCSC3 suppressed cervical carcinoma cell invasion and proliferation via regulating miR-574-5p.

Authors:  Min Zhang; Yinghui Song; Lijuan Yu
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

Review 3.  The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

Authors:  Utpalendu Paul; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-03-02       Impact factor: 2.742

Review 4.  Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring.

Authors:  Yangkun Zhou; Yang Yue; Siyu Fan; Qiaojun Jia; Xianfeng Ding
Journal:  Mol Biotechnol       Date:  2021-07-10       Impact factor: 2.695

Review 5.  Mechanistic Involvement of Long Non-Coding RNAs in Oncotherapeutics Resistance in Triple-Negative Breast Cancer.

Authors:  Samarth Kansara; Vijay Pandey; Peter E Lobie; Gautam Sethi; Manoj Garg; Amit Kumar Pandey
Journal:  Cells       Date:  2020-06-21       Impact factor: 6.600

Review 6.  Long Non-Coding RNA in the Pathogenesis of Cancers.

Authors:  Yujing Chi; Di Wang; Junpei Wang; Weidong Yu; Jichun Yang
Journal:  Cells       Date:  2019-09-01       Impact factor: 6.600

7.  Long Noncoding RNA RP11-334E6.12 Promotes the Proliferation, Migration and Invasion of Breast Cancer Cells Through the EMT Pathway by Activating the STAT3 Cascade.

Authors:  Dongjun Sun; Hengming Liu; Tiantian Wang
Journal:  Cancer Manag Res       Date:  2020-02-13       Impact factor: 3.989

Review 8.  Epigenetic Alterations in Triple-Negative Breast Cancer-The Critical Role of Extracellular Matrix.

Authors:  Vasiliki Zolota; Vasiliki Tzelepi; Zoi Piperigkou; Helen Kourea; Efthymia Papakonstantinou; Μaria-Ioanna Argentou; Nikos K Karamanos
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

Review 9.  LncRNA H19: A novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

10.  Long Non-coding RNA RP11-480I12.5 Promotes the Proliferation, Migration, and Invasion of Breast Cancer Cells Through the miR-490-3p-AURKA-Wnt/β-Catenin Axis.

Authors:  Xinya Gao; Yuanhui Lai; Zhanqiang Zhang; Yanfei Ma; Zhizhai Luo; Yanghong Li; Ciqiu Yang; Guanming Lu; Jie Li
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.